Saturday, 20 July 2024

Australia's most trusted
source of pharma news

Saturday, 20 July 2024
Listen to this story 

MSAC brands J&J 'unethical'

Posted 8 July 2024 AM

MSAC has branded a pricing proposal by Johnson & Johnson Innovative Medicine as 'unethical' - exposing the depth of bitterness in negotiations which have ended with the company's CAR T therapy for multiple myeloma, Carvykti, finally winning a recommendation.

The long-awaited good news for patients came hand-in-hand with a scathing rebuke from MSAC delivered in the 11-page Public Summary Document, which some are privately terming a "dummy spit" by the Committee, unhappy about the very public campaign which questioned why a recommendation was so slow coming.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (15)

Clinical & Medical, R&D (15)

Regulatory, Pharmacovigilance & QA (9)

Other (28)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.